Compare IIF & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IIF | ELTX |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.5M | 185.4M |
| IPO Year | N/A | 2014 |
| Metric | IIF | ELTX |
|---|---|---|
| Price | $22.95 | $2.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 33.3K | ★ 877.0K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 13.94% | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.83 | $2.66 |
| 52 Week High | $27.99 | $16.00 |
| Indicator | IIF | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 34.75 |
| Support Level | $22.01 | $2.72 |
| Resistance Level | $23.66 | $5.38 |
| Average True Range (ATR) | 0.42 | 0.22 |
| MACD | -0.01 | 0.21 |
| Stochastic Oscillator | 73.11 | 20.31 |
Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.